NM26-2198

· Yellow Jersey Therapeutics AG

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NM26-2198, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD) [Phase 1]

See pricing